2024
Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
McCoy R, Herrin J, Swarna K, Deng Y, Kent D, Ross J, Umpierrez G, Galindo R, Crown W, Borah B, Montori V, Brito J, Neumiller J, Mickelson M, Polley E. Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk. Nature Cardiovascular Research 2024, 3: 431-440. PMID: 38846711, PMCID: PMC11156225, DOI: 10.1038/s44161-024-00453-9.Peer-Reviewed Original ResearchAdverse cardiovascular eventsGlucose-lowering medicationsType 2 diabetesCardiovascular diseaseGLP-1RACardiovascular eventsGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsRetrospective cohort studyCardiovascular disease risk reductionGlucose-lowering agentsModerate cardiovascular riskCardiovascular risk reductionReceptor agonistsEffects of glucose-lowering medicationsRisk reductionCardiovascular riskCohort studyCardiovascular outcomesHigh riskBaseline riskModerate riskEnrollment in High-Deductible Health Plans and Incident Diabetes Complications
McCoy R, Swarna K, Jiang D, Van Houten H, Chen J, Davis E, Herrin J. Enrollment in High-Deductible Health Plans and Incident Diabetes Complications. JAMA Network Open 2024, 7: e243394. PMID: 38517436, PMCID: PMC10960199, DOI: 10.1001/jamanetworkopen.2024.3394.Peer-Reviewed Original ResearchConceptsHigh-deductible health plansHealth plansChronic disease managementOdds of myocardial infarctionLower-extremity complicationsMixed-effects logistic regression modelsOut-of-pocket costsAssociated with increased oddsDiabetic complicationsInverse propensity score weightingLogistic regression modelsCardiovascular risk factorsEmployer-sponsored health plansDiabetes careRetrospective cohort studyUS adultsPropensity score weightingPotential selection biasMain OutcomesCohort studyBaseline yearIncident complicationsDisease managementMixed-effectsPotential harmDisparities in Acute and Chronic Complications of Diabetes Along the U.S. Rural-Urban Continuum.
Steiger K, Herrin J, Swarna K, Davis E, McCoy R. Disparities in Acute and Chronic Complications of Diabetes Along the U.S. Rural-Urban Continuum. Diabetes Care 2024, 47: 818-825. PMID: 38387066, PMCID: PMC11043221, DOI: 10.2337/dc23-1552.Peer-Reviewed Original ResearchResidents of remote areasRural-urban continuumHazard ratioLower-extremity complicationsHazard of myocardial infarctionMedicare Advantage beneficiariesRemote areasHazard of strokeOptumLabs Data WarehouseComplications of diabetesLower hazardMyocardial infarctionRetrospective cohort studyHeart failureDiabetic complicationsCohort studyResidents of small townsEnd-stage kidney diseaseSmall townsChronic complications of diabetesChronic diabetic complicationsResidentsDiabetesDisparitiesChronic complications
2022
Factors Associated With Disparities in Hospital Readmission Rates Among US Adults Dually Eligible for Medicare and Medicaid
Silvestri D, Goutos D, Lloren A, Zhou S, Zhou G, Farietta T, Charania S, Herrin J, Peltz A, Lin Z, Bernheim S. Factors Associated With Disparities in Hospital Readmission Rates Among US Adults Dually Eligible for Medicare and Medicaid. JAMA Health Forum 2022, 3: e214611. PMID: 35977231, PMCID: PMC8903116, DOI: 10.1001/jamahealthforum.2021.4611.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionNon-DE patientsCommunity-level factorsHospital disparitiesHeart failureDE patientsReadmission ratesCohort studyUS hospitalsRisk-adjusted readmission ratesRetrospective cohort studyHospital readmission ratesLow-income older adultsHospital quality improvementEligible patientsHospital readmissionMedicaid eligibility policyCare transitionsMyocardial infarctionState Medicaid policiesWorse outcomesMedicare patientsMAIN OUTCOMEUS adultsPneumonia
2021
Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases
Singh S, Heien HC, Herrin J, Dulai PS, Sangaralingham L, Shah ND, Sandborn WJ. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology And Hepatology 2021, 20: e74-e88. PMID: 33640480, PMCID: PMC8384969, DOI: 10.1016/j.cgh.2021.02.032.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseSerious infectionsMarginal structural Cox proportional hazards modelsCox proportional hazards modelBaseline disease characteristicsRetrospective cohort studyAdministrative claims databaseProportional hazards modelTime-varying useCohort studyBowel diseaseTreatment initiationUlcerative colitisHealthcare utilizationClaims databaseDisease characteristicsTumor necrosisVedolizumabLower riskHazards modelPatientsInfectionAntagonistInsurance coverageRisk
2020
Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features
Pathak R, Goldberg SB, Canavan M, Herrin J, Hoag JR, Salazar MC, Papageorge M, Ermer T, Boffa DJ. Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features. JAMA Oncology 2020, 6: 1741-1750. PMID: 32940636, PMCID: PMC7499246, DOI: 10.1001/jamaoncol.2020.4232.Peer-Reviewed Original ResearchConceptsNode-negative non-small cell lung cancerHigh-risk pathologic featuresNon-small cell lung cancerAdjuvant chemotherapyCell lung cancerPathologic featuresTumor sizeSurvival benefitCohort studyLung cancerNode-negative NSCLCEarly-stage non-small cell lung cancerCox proportional hazards regression modelHigh-risk clinicopathologic featuresProportional hazards regression modelsNational Cancer DatabaseRetrospective cohort studyTreatment-naive patientsAdjuvant chemotherapy useHigh-risk featuresAssociation of survivalHazards regression modelsImmortal time biasChemotherapy useEligible patientsIlluminating Hospital Disparities in Readmissions for Patients with Social Risk Factors: Comparing Hospital Performance Using Two Different Approaches
Herrin J, Peltz A, Zhou S, Du C, Barbo A, Charania S, Schwartz M, Lin Z, Bernheim S. Illuminating Hospital Disparities in Readmissions for Patients with Social Risk Factors: Comparing Hospital Performance Using Two Different Approaches. Health Services Research 2020, 55: 93-94. PMCID: PMC7440563, DOI: 10.1111/1475-6773.13462.Peer-Reviewed Original ResearchSocial risk factorsAbsolute risk differenceDual eligibility statusHospital disparitiesRisk factorsDual eligibilityMedicare patientsReadmission ratesOdds ratioRisk differenceSocioeconomic disparitiesMedicare FFS patientsRetrospective cohort studyClinical risk factorsCommon clinical conditionHospitalized Medicare patientsSES indexStandard Analytic FilesVeterans Affairs hospitalEligibility statusMedicare Part AHospital outcomesCohort studyFFS patientsHospital readmissionRisk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice
Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmology 2020, 128: 417-424. PMID: 32781110, DOI: 10.1016/j.ophtha.2020.07.062.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsBevacizumabCerebrovascular DisordersDrug-Related Side Effects and Adverse ReactionsFemaleHemorrhageHospitalizationHumansIntravitreal InjectionsMaleMyocardial InfarctionRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal DiseasesRetrospective StudiesRisk AssessmentVascular Endothelial Growth Factor AConceptsNeovascular age-related macular degenerationRetinal venous occlusive diseaseDiabetic retinal diseaseSystemic serious adverse eventsAnti-VEGF injectionsAnti-VEGF agentsMajor bleedingAcute myocardial infarctionCause hospitalizationCerebrovascular diseaseRoutine clinical practiceMyocardial infarctionIntravitreal bevacizumabTreatment initiationAdverse eventsPropensity score-weighted Cox proportional hazards modelClinical practiceLarge U.S. administrative claims databaseRisk of MICox proportional hazards modelU.S. administrative claims databaseAge-related macular degenerationRisk-adjusted effectSystemic safety profileRetrospective cohort study
2019
Home Health Care After Skilled Nursing Facility Discharge Following Heart Failure Hospitalization
Weerahandi H, Bao H, Herrin J, Dharmarajan K, Ross JS, Jones S, Horwitz LI. Home Health Care After Skilled Nursing Facility Discharge Following Heart Failure Hospitalization. Journal Of The American Geriatrics Society 2019, 68: 96-102. PMID: 31603248, PMCID: PMC6964248, DOI: 10.1111/jgs.16179.Peer-Reviewed Original ResearchConceptsSkilled nursing facilitiesHF hospitalizationReadmission ratesReadmission riskHeart failure readmission ratesDays of dischargeHeart failure hospitalizationRetrospective cohort studyHospital discharge practicesMore functional impairmentHome health careFailure hospitalizationHF patientsUnplanned readmissionCohort studyHospital dischargePrimary outcomeRestorative therapySNF stayFunctional impairmentHome healthcare servicesService Medicare dataAdjusted modelCox modelNursing facilitiesRacial and Ethnic Differences in 30-Day Hospital Readmissions Among US Adults With Diabetes
Rodriguez-Gutierrez R, Herrin J, Lipska KJ, Montori VM, Shah ND, McCoy RG. Racial and Ethnic Differences in 30-Day Hospital Readmissions Among US Adults With Diabetes. JAMA Network Open 2019, 2: e1913249. PMID: 31603490, PMCID: PMC6804020, DOI: 10.1001/jamanetworkopen.2019.13249.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAged, 80 and overAsianBlack or African AmericanComorbidityDiabetes ComplicationsEthnicityFemaleHispanic or LatinoHospital Bed Capacity, 300 to 499Hospital Bed Capacity, 500 and overHospitals, UniversityHospitals, VoluntaryHumansIncomeMaleMiddle AgedMinority GroupsPatient ReadmissionRacial GroupsRetrospective StudiesUnited StatesWhite PeopleConceptsCause readmissionIndex hospitalizationBlack patientsWhite patientsUS adultsHigh riskAdministrative claims data setsHospital-level risk factorsEthnic differencesLarge hospitalsPlace of hospitalizationDays of dischargeRetrospective cohort studyLow-income patientsMedicare Advantage beneficiariesSystem-level factorsClaims data setsHealth care qualityRace/ethnicityCohort studyReadmission ratesAdult patientsHospital readmissionHispanic patientsReadmission riskRisk of Readmission After Discharge From Skilled Nursing Facilities Following Heart Failure Hospitalization: A Retrospective Cohort Study
Weerahandi H, Li L, Bao H, Herrin J, Dharmarajan K, Ross JS, Kim KL, Jones S, Horwitz LI. Risk of Readmission After Discharge From Skilled Nursing Facilities Following Heart Failure Hospitalization: A Retrospective Cohort Study. Journal Of The American Medical Directors Association 2019, 20: 432-437. PMID: 30954133, PMCID: PMC6486375, DOI: 10.1016/j.jamda.2019.01.135.Peer-Reviewed Original ResearchConceptsSkilled nursing facilitiesSNF dischargeRetrospective cohort studySNF lengthHeart failureHF hospitalizationComposite outcomeCohort studyNursing facilitiesService beneficiaries 65Heart failure hospitalizationRisk of readmissionHazard rate ratiosFailure hospitalizationUnplanned readmissionHF diagnosisHospital dischargePostdischarge outcomesSNF stayMedicare patientsMedicare feeHome transitionPatientsReadmissionDay 3
2018
Risk of Systemic Adverse Events Associated with Intravitreal Anti–VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice
Maloney MH, Schilz SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of Systemic Adverse Events Associated with Intravitreal Anti–VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice. Ophthalmology 2018, 126: 1007-1015. PMID: 30292542, DOI: 10.1016/j.ophtha.2018.09.040.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaRoutine clinical practiceSystemic serious adverse eventsMacular laserMajor bleedingCerebrovascular diseaseMyocardial infarctionClinical practiceCause hospitalizationAdverse eventsHazard ratioIntravitreal corticosteroidsAnti-VEGFMacular edemaDME treatmentTreatment of DMEIntravitreal anti-VEGF therapyCox proportional hazards regressionAnti-VEGF pharmacotherapySystemic safety profileCorticosteroid-treated patientsRetrospective cohort studySerious adverse eventsSystemic adverse eventsMacular laser photocoagulation
2017
Regional Medicare Expenditures and Survival Among Older Women With Localized Breast Cancer
Tannenbaum S, Soulos PR, Herrin J, Mougalian S, Long JB, Wang R, Ma X, Gross CP, Xu X. Regional Medicare Expenditures and Survival Among Older Women With Localized Breast Cancer. Medical Care 2017, 55: 1030-1038. PMID: 29068906, PMCID: PMC5863278, DOI: 10.1097/mlr.0000000000000822.Peer-Reviewed Original ResearchConceptsBreast cancer careHospital referral regionsNonmetastatic breast cancerBreast cancerCancer careMedicare beneficiariesMedicare expendituresCancer expendituresBetter survivalEnd Results-MedicareRetrospective cohort studyPatients 3 yearsClinical characteristicsCohort studyOverall survivalCancer stagePatient outcomesOutcome measuresReferral regionsOlder womenSignificant associationStage IIBivariate analysisCancerQuintilePredictors of Return Visits Among Insured Emergency Department Mental Health and Substance Abuse Patients, 2005-2013
Lee S, Herrin J, Bobo WV, Johnson R, Sangaralingham LR, Campbell RL. Predictors of Return Visits Among Insured Emergency Department Mental Health and Substance Abuse Patients, 2005-2013. Western Journal Of Emergency Medicine 2017, 18: 884-893. PMID: 28874941, PMCID: PMC5576625, DOI: 10.5811/westjem.2017.6.33850.Peer-Reviewed Original ResearchConceptsED visitsReturn visitsInpatient admissionsOptum Labs Data WarehouseMental healthChronic medical comorbiditiesContinuous insurance enrollmentFirst ED visitIndex ED visitRetrospective cohort studyAdministrative claims dataMedicare Advantage enrolleesPrior EDMedical comorbiditiesCohort studyAcute carePrimary diagnosisStudy inclusionRisk factorsInpatient utilizationClaims dataIncreased ageSubstance abusePatientsStudy period
2016
Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions
Desai NR, Ross JS, Kwon JY, Herrin J, Dharmarajan K, Bernheim SM, Krumholz HM, Horwitz LI. Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions. JAMA 2016, 316: 2647-2656. PMID: 28027367, PMCID: PMC5599851, DOI: 10.1001/jama.2016.18533.Peer-Reviewed Original ResearchConceptsHospital Readmissions Reduction ProgramAcute myocardial infarctionReadmission ratesReadmissions Reduction ProgramHeart failurePenalty statusNontarget conditionsMedicare feeMean readmission rateThirty-day riskRetrospective cohort studyUnplanned readmission rateReduction programsHRRP announcementHRRP implementationPenalized hospitalsCohort studyService patientsMyocardial infarctionMAIN OUTCOMEExcess readmissionsMedicare beneficiariesService beneficiariesHospitalPatientsTrends in Utilization and Outcomes of Hip Arthroscopy in the United States Between 2005 and 2013
Maradit Kremers H, Schilz SR, Van Houten HK, Herrin J, Koenig KM, Bozic KJ, Berry DJ. Trends in Utilization and Outcomes of Hip Arthroscopy in the United States Between 2005 and 2013. The Journal Of Arthroplasty 2016, 32: 750-755. PMID: 27793498, DOI: 10.1016/j.arth.2016.09.004.Peer-Reviewed Original ResearchConceptsTotal hip arthroplastyHip arthroscopy proceduresHip arthroscopyArthroscopy proceduresSubsequent hip arthroscopyCumulative incidenceArthroscopy ratesRetrospective cohort studySubset of patientsAdministrative claims dataCohort studyTHA proceduresSubsequent riskHip arthroplastyClaims dataArthroscopyUtilization trendsSubsequent proceduresSurvival analysis methodsSubsequent arthroscopyOutcomesIncidenceFuture studiesLarge increaseAge